Basic Information
| LncRNA/CircRNA Name | A2M-AS1 |
| Synonyms | NA |
| Region | GRCh38_12:9065177-9068060 |
| Ensemble | ENSG00000245105 |
| Refseq | NR_026971 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR, Western blot etc. |
| Sample | breast cancer patients tumour tissues and adjacent normal tissues,breast cancer cell lines (BT-549, ZR-75-30, Hs578T, and MDA-MB-231) |
| Expression Pattern | up-regulated |
| Function Description | A2M-AS1 exerts regulatory effects on downstream factors in the cell adhesion molecule pathway, including CD2 and SELL. These results imply that A2M-AS1 might be a promising candidate prognostic factor and therapeutic target for breast cancer. |
| Pubmed ID | 32352014 |
| Year | 2020 |
| Title | Screening of a Novel Upregulated lncRNA, A2M-AS1, That Promotes Invasion and Migration and Signifies Poor Prognosis in Breast Cancer. |
External Links
| Links for A2M-AS1 | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |